Understanding how Foxf2 affects prostate cancer progression
Stromal Foxf2 suppresses prostate cancer progression
This study is looking at how a specific gene called Foxf2 affects prostate cancer, especially in figuring out which tumors are more aggressive, so that doctors can better identify and treat patients who need it most.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Washington NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project ID | NIH-11124725 on NIH RePORTER |
What this research studies
This research investigates the role of the Foxf2 gene in prostate cancer, particularly how it influences the aggressiveness of tumors in different regions of the prostate. By analyzing gene expression in the stroma of prostate tissues, the study aims to identify markers that can differentiate between indolent and aggressive forms of prostate cancer. Patients with lower Gleason Scores may be monitored without immediate treatment, but this research seeks to improve early detection and intervention for those with more aggressive tumors. The findings could lead to better personalized treatment strategies for prostate cancer patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are American men diagnosed with prostate cancer, particularly those with lower Gleason Scores under active surveillance.
Not a fit: Patients with advanced or metastatic prostate cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved methods for identifying aggressive prostate cancers, allowing for timely and appropriate treatment.
How similar studies have performed: Other research has shown promise in identifying molecular markers for cancer aggressiveness, suggesting that this approach could yield valuable insights.
Where this research is happening
Seattle, United States
- University of Washington — Seattle, United States (Active)
Researchers
- Principal investigator: Xin, Li — University of Washington
- Study coordinator: Xin, Li
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.